IFI30 Is a Novel Immune-Related Target with Predicting Value of Prognosis and Treatment Response in Glioblastoma
Chen Zhu,Xin Chen,Gefei Guan,Cunyi Zou,Qing Guo,Peng Cheng,Wen Cheng,Anhua Wu
DOI: https://doi.org/10.2147/OTT.S237162
IF: 4
2020-02-06
OncoTargets and Therapy
Abstract:Chen Zhu, * Xin Chen, * Gefei Guan, Cunyi Zou, Qing Guo, Peng Cheng, Wen Cheng, Anhua Wu Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China *These authors contributed equally to this work Correspondence: Anhua Wu Department of Neurosurgery, The First Hospital of China Medical University, Nanjing Street 155, Heping District, Shenyang 110001, People's Republic of China Tel +86 24-83283301 Fax +86 24-83283133 Email ahwu@cmu.edu.cn Wen Cheng Department of Neurosurgery, The First Hospital of China Medical University, Nanjing Street 155, Heping District, Shenyang 110001, People's Republic of China Tel +86 24-83283129 Fax + 86 24-83283133 Email cmu071207@163.com Purpose: As a crucial part of anti-tumor immunotherapy, interferon-α/β (IFN-α/β) treatment has been broadly applied to clinical trials of glioma. However, less is known about implement of interferon-γ (IFN-γ) in glioma. Further investigating the valuable hub molecular of IFN-γ family might provide us a novel guidance for glioma therapy. Methods: This study carried out an analysis on glioma patients from the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) cohorts. The analyses were performed by GraphPad Prism 8 and R language. All the validated experiments were performed three times independently. Results: We identified IFI30 as the most stable independent prognostic gene among 20 classical IFN-γ stimulated genes (ISGs) in glioma patients. Furthermore, we found that IFI30 highly expressed in malignant subtypes of glioma and associated with chemotherapy response. We also found IFI30 could activate IL6-STAT6 signal pathway to decline the glioma cells' chemotherapy sensitivity by performing experiments. Gene ontology (GO) analysis showed IFI30 associated with enhanced leucocyte mediated immune and inflammatory response. Microenvironment analysis referred that high IFI30 expression accompanied with more infiltration of M2 type macrophages. Conclusion: IFI30 is involved in the malignant progression and chemotherapy response of glioblastoma, which can be a potential target for treatment in glioblastoma patients. Keywords: glioblastoma, IFI30, prognosis, microenvironment, temozolomide
oncology,biotechnology & applied microbiology